LL-37 · Research brief

LL-37: Mechanism, Research Evidence, and Laboratory Handling

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

46 WORDS

Short answer

LL-37 is a 37-residue cationic antimicrobial peptide and the only cathelicidin identified in humans, cleaved from the precursor protein hCAP18 in neutrophils and epithelial tissue. Laboratory research examines its membrane-disrupting antimicrobial activity, biofilm interactions, immune signaling roles, and effects on wound repair, skin, and mucosal biology.

Key takeaways

LL-37 is a 37-residue cationic antimicrobial peptide cleaved from the precursor hCAP18 — the only cathelicidin identified in humans.
Its reported mechanism is dual: direct interaction with negatively charged microbial membranes, plus receptor-mediated immune signaling in host cells.
Published work spans antimicrobial and biofilm studies, skin and oral biology, mucosal epithelium, and lipid handling — much of it in vitro or in animal models.
The same membrane activity that disrupts microbes has been reported to affect host cells at higher concentrations, making concentration-dependence a central research variable.
LL-37 is not FDA-approved for any of the applications discussed here and is intended for laboratory research use only.
Batch-level third-party COAs with HPLC purity, mass spectrometry identity, and traceable lot numbers are the practical basis for evaluating material quality.

What LL-37 Is and Where It Came From

Cathelicidins are a family of host-defense peptides found across many vertebrate species. Humans express exactly one: the gene CAMP, which produces an 18-kDa precursor protein called hCAP18. That precursor is largely inert until proteases — proteinase 3 in neutrophils, kallikreins in skin — cleave off the C-terminal fragment. That fragment is LL-37, named for its two leading leucine residues and its 37-amino-acid length.

The peptide is strongly cationic at physiological pH and adopts an amphipathic alpha-helical conformation once it encounters a membrane or a helix-promoting environment. Those two properties — net positive charge and a face-separated helix — explain most of what LL-37 does in an assay tube. It is produced by neutrophils, monocytes, keratinocytes, and the epithelial linings of the airway, gut, and reproductive tract, and it is also measurable in saliva, sweat, breast milk, and wound fluid.

The vitamin D connection

The CAMP promoter contains a vitamin D response element, and biochemical work reports that active vitamin D metabolites upregulate hCAP18/LL-37 transcription in several human cell types. This is one of the more frequently cited pieces of LL-37 biology because it links a nutrient pathway to an innate-immune effector. Notably, one line of laboratory work using this induction system has also described concentration-dependent cytotoxicity toward human osteoblasts — a reminder that endogenous induction and exogenous exposure are not equivalent experimental conditions.

Reported Mechanism of Action

LL-37 is usually described as having two mechanistic arms that operate on different timescales and at different concentrations.

Direct membrane interaction

Bacterial membranes present a high density of anionic phospholipids and, in Gram-negative organisms, lipopolysaccharide. The cationic face of LL-37 associates electrostatically with these surfaces; the hydrophobic face then inserts into the lipid bilayer. Depending on peptide concentration and lipid composition, biophysical studies describe carpet-like surface accumulation, transient pore formation, and eventual membrane permeabilization. Because this is a physicochemical interaction rather than an enzyme-target fit, resistance development is generally reported to be slower than with conventional small-molecule antibiotics — though "slower" is not "absent," and bacterial proteases and surface modifications that blunt cationic peptides are well documented.

Biofilm and matrix effects

Separately from killing planktonic cells, in vitro work reports that LL-37 can interfere with biofilm formation at sub-inhibitory concentrations — affecting attachment, quorum-sensing signaling, and twitching motility in some species. Much of the interest in this peptide within chronic-infection research communities traces back to these biofilm observations rather than to its raw minimum inhibitory concentrations.

Host-cell signaling and immunomodulation

LL-37 also behaves as a signaling molecule. It has been reported to engage formyl peptide receptor 2 (FPR2/FPRL1), to transactivate EGFR, and to influence P2X7 and Toll-like receptor pathways. Downstream effects described in the literature include chemotaxis of neutrophils, monocytes, and T cells; modulation of cytokine and chemokine output; effects on angiogenesis and keratinocyte migration; and neutralization of LPS-driven inflammatory signaling. A further well-characterized behavior is complex formation with self-DNA and self-RNA, which can render nucleic acids visible to endosomal Toll-like receptors — a mechanism repeatedly invoked in autoimmune and inflammatory skin research.

What the Research Literature Examines

Evidence maturity varies sharply by area. The table below is a coarse map, not a ranking of clinical usefulness.

Research area	Typical model	Maturity of evidence
Antimicrobial and antibiofilm activity	In vitro, isolated organisms	Extensive in vitro; limited translation
Skin and dermatologic inflammation	Human keratinocytes, patient tissue	Mechanistic and observational
Oral and periodontal biology	Human saliva and crevicular fluid	Biomarker-level, early
Gut and mucosal epithelium	Cell monolayers, colonic tissue	Mechanistic, mixed directionality
Lipid handling and metabolism	Rodent and biochemical models	Preliminary
Wound repair and angiogenesis	In vitro and animal models	Suggestive, not confirmatory

Antimicrobial and biofilm research

The largest body of work is microbiological. LL-37 shows broad in vitro activity against Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, with potency that is highly sensitive to assay conditions — salt concentration, serum proteins, and pH all shift results substantially. This condition-dependence is one reason in vitro potency has not translated simply into clinical outcomes, and it is a variable worth controlling explicitly in any comparative protocol.

Skin, oral, and mucosal biology

Dermatologic research has been particularly active. Transcriptomic work in human keratinocytes reports that LL-37 exposure induces chemokine programs — including CXCL10 through Jak/STAT signaling — that have been linked to T-cell recruitment in rosacea pathogenesis. Immunohistochemical studies have also examined cathelicidin expression in vitiligo skin. In dentistry, LL-37 levels in oral fluids have been evaluated as a response biomarker following non-surgical periodontal therapy, and salivary cathelicidin has been measured in pediatric populations living with HIV. These are association and mechanism studies; none establishes LL-37 as a therapy.

Gut epithelium and barrier integrity

Membrane biophysics work reports that human LL-37 can rapidly compromise colonic epithelial integrity at sufficient exposure — a finding that complicates simple "more cathelicidin is better" framings and reinforces that host and microbial membranes differ in degree, not in kind. Researchers examining gut-focused questions, including small intestinal bacterial overgrowth, generally treat concentration-dependence and barrier readouts as primary endpoints rather than afterthoughts.

Metabolic and cardiovascular directions

Newer biochemical work describes an interaction between LL-37 and ApoB-100 that has been reported to promote LDL clearance and reduce hepatic cholesterol accumulation in model systems. This represents an unexpected direction for a peptide historically studied as an antimicrobial, and evidence remains preliminary. Comparable exploratory work has examined cathelicidin expression in fibrotic tissue such as breast implant capsules, and structural parallels between LL-37 aggregation behavior and amyloid-forming peptides have attracted mechanistic attention.

Areas discussed widely but studied thinly

LL-37 appears frequently in practitioner and community discussion around chronic tick-borne illness, mold-related inflammatory syndromes, and persistent gut dysbiosis. Controlled human data in these specific contexts are sparse to absent. Researchers approaching these questions should treat community-reported observations as hypothesis-generating only, and should not conflate the volume of online discussion with the volume of published evidence.

Laboratory Handling: Reconstitution and Storage

LL-37 is typically produced as a lyophilized powder and behaves like other cationic, helix-forming peptides in the laboratory — meaning it is more sensitive to handling than most small molecules. General practices reported across peptide laboratories include:

Equilibrate before opening. Allowing sealed vials to reach ambient temperature before breaking the seal limits condensation, which is a common and avoidable source of hydrolytic degradation.
Reconstitute gently. Solvent is generally directed down the vial wall rather than injected onto the peptide cake, and the vial is swirled rather than shaken or vortexed. Mechanical agitation promotes aggregation in amphipathic peptides.
Mind the surface. Cationic peptides adsorb to glass and some plastics, which can silently lower effective concentration in dilute preparations. Low-binding labware is often preferred.
Protect from repeated freeze-thaw. Aliquoting a reconstituted preparation into single-use volumes is standard practice; each thaw cycle is a degradation opportunity.
Store cold and dark. Lyophilized material is generally held frozen for long-term retention; reconstituted material is held refrigerated for short working windows and frozen for longer ones, protected from light.
Watch for visual change. Cloudiness, visible particulates, discoloration, or failure to redissolve cleanly are practical indicators that a preparation should not be used for quantitative work.

Specific solvent choices, concentrations, and hold times belong to the individual protocol and to the documentation accompanying a given batch — not to a general overview.

Regulatory and Research-Use Status

This deserves plain language. LL-37 is not approved by the FDA for the treatment, prevention, or management of any of the conditions discussed on this page. It is not a dietary ingredient, not a compounded medication with an established indication, and not a consumer product. Research-grade LL-37 is intended for laboratory research use only, by qualified investigators, in controlled settings, and is not intended for human or veterinary use, diagnostic procedures, or food applications.

Clinical development of cathelicidin-derived peptides has faced recurring obstacles that any literature review will surface: proteolytic instability in biological fluids, loss of activity in physiological salt and serum, and the host-cell effects noted above at higher concentrations. Several engineered analogues and fragments have been explored specifically to address these constraints. None of this changes the regulatory status of the parent peptide.

How Researchers Evaluate Material Quality

Because peptide identity and purity cannot be assessed by eye, documentation is the entire basis of quality assessment. The following criteria are what experienced laboratories actually check.

Document or test	What it establishes	What to look for
Third-party COA	Independent verification	An outside analytical laboratory, not an in-house claim
HPLC chromatogram	Purity percentage	The actual trace, not just a number; clean main peak, characterized minor peaks
Mass spectrometry	Molecular identity	Observed mass consistent with the expected LL-37 mass
Batch or lot number	Traceability	The lot on the vial matches the lot on the COA
Analysis date	Currency of testing	Testing performed on the batch in hand, not a legacy report

Two additional habits distinguish rigorous evaluation. First, a COA should be batch-specific: a single representative certificate reused across many production runs tells a researcher nothing about the vial on the bench. Second, purity and identity are separate questions — a highly pure preparation of the wrong sequence is still the wrong sequence, which is why mass spectrometry belongs alongside HPLC rather than instead of it. Publishing COAs per batch is the transparency standard researchers should expect from any supplier.

Where the Open Questions Are

LL-37 is unusually well characterized biochemically and unusually poorly characterized translationally. The gaps most often flagged in the literature include:

Concentration windows. The separation between antimicrobial activity and host-cell effects is narrow in several model systems, and it is not consistent across cell types or assay conditions.
Physiological relevance of in vitro potency. Salt, serum albumin, and glycosaminoglycans all attenuate activity. How much of the in vitro literature survives translation to physiological milieu is unresolved.
Dual role in inflammation. The same peptide is described as anti-inflammatory in endotoxin neutralization and pro-inflammatory in nucleic-acid-complex signaling. What determines which behavior dominates is an active question.
Stability and exposure. Rapid proteolysis in biological fluids means measured concentrations and functional exposure may diverge substantially.
Biomarker versus effector. In several human studies, LL-37 is measured as a correlate of disease activity. Whether it is driving those processes, responding to them, or both is generally not established.
Untested indications. The chronic-illness applications most discussed online are the least represented in controlled research.

For researchers building a protocol, the practical takeaway is that LL-37 is best treated as a well-defined molecule with an under-defined translational profile: strong biochemistry, hedged conclusions, and endpoints that should include host-cell readouts rather than antimicrobial metrics alone.

Research-grade LL-37: Real Peptides supplies LL-37 for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore LL-37 research on Real Peptides

The articles below go deeper on the questions researchers ask most about LL-37.

Buying & quality

Research timelines & mechanisms

Research questions

Stacks & comparisons

Reconstitution, storage & handling

Safety & side effects

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions

They are related but not interchangeable. Cathelicidin is the peptide family; hCAP18 is the 18-kDa human precursor protein encoded by the CAMP gene; LL-37 is the active 37-amino-acid C-terminal fragment released when proteases cleave hCAP18. Papers sometimes write "hCAP18/LL-37" when measuring the precursor and fragment together, which matters when comparing quantitative results across studies.

The CAMP gene promoter contains a vitamin D response element, so active vitamin D metabolites upregulate hCAP18/LL-37 transcription in several human cell types. This link is frequently cited in innate-immunity literature. Importantly, endogenous induction through this pathway is a different experimental condition than exogenous peptide exposure, and results from one should not be assumed to apply to the other.

In vitro studies report that LL-37 can interfere with biofilm formation at concentrations below those needed to kill planktonic bacteria, affecting attachment, quorum-sensing signaling, and motility in certain species. These findings drive much of the interest in the peptide. They are laboratory observations under defined conditions; translation to complex biological environments remains largely unexamined.

LL-37 is not FDA-approved for the treatment or prevention of any condition discussed here. Research-grade material is intended for laboratory research use only and is not for human or veterinary use. Development challenges reported in the literature include proteolytic instability, activity loss in physiological salt and serum, and host-cell effects at higher concentrations.

Through batch-specific documentation. An HPLC chromatogram establishes purity and shows the actual trace rather than a bare percentage; mass spectrometry confirms that the observed molecular mass matches the expected LL-37 sequence. A third-party certificate of analysis, a lot number matching the vial, and a recent analysis date complete the picture. Purity and identity are separate questions requiring separate tests.

Because activity is highly condition-dependent. Salt concentration, serum albumin, glycosaminoglycans, and pH all attenuate the electrostatic interaction that drives membrane binding. A peptide potent in low-salt buffer may show markedly reduced activity in serum-containing media. Reporting exact assay conditions is therefore essential when comparing published potency values across laboratories.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA